Product Description
Mechanisms of Action: N/A
Novel Mechanism: No
Modality: N/A
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Algeria | Belgium | France | India | Lebanon | Morocco | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/28/2025 |
News Article |
Nucleai to Showcase Expanded Suite of ADC Biomarker Scoring Solutions at ASCO 2025 |
|
04/22/2025 |
News Article |
Lunit Showcases AI Pathology Advances in Cancer Research from Rare to Common Tumors at AACR 2025 |
|
04/21/2025 |
News Article |
PathAI Announces Poster Presentations at the 2025 American Association of Cancer Research Annual Meeting |
|
03/26/2025 |
News Article |
Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca |